Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding
A partir d'une revue systématique de la littérature publiée entre janvier 2006 et avril 2020 (31 études, 119 053 patients), cette méta-analyse évalue le délai de survenue d'un carcinome hépatocellulaire après une utilisation d'antirétroviraux (fumarate de ténofovir disoproxil ou entécavir) chez des patients atteints d'une hépatite B
The risk of hepatocellular carcinoma associated with antiviral therapies has been a source of greatcontroversy in clinical hepatology over the past few years. Initially an increased risk of hepatocellular carcinoma was proposed with direct-acting antiviral therapy for chronic hepatitis C virus (HCV) infection compared with interferon-based therapy. The original-epidemiologically flawed-study from Spain led to considerable concern among clinicians, and presumably patients, and was followed by a plethora of studies and meta-analyses.
The Lancet Gastroenterology & Hepatology , commentaire en libre accès, 2019